{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:27:24Z","timestamp":1782178044025,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["2019S015"],"award-info":[{"award-number":["2019S015"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Sodium\u2010glucose cotransporter\u20102 inhibitors (SGLT\u20102i) have been commercialized in France for type 2 diabetes since April 2020 and later for heart and renal diseases. Given the recent developments in treating diabetes and the widening of SGLT\u20102i indications, we aimed to study changes in the use of glucose\u2010lowering drugs in France and to characterize SGLT\u20102i new users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a nationwide utilization study using the French health insurance database. Trends in incidence and prevalence of glucose\u2010lowering drug use were assessed by a repeated cross\u2010sectional study in 2019 and 2021. A cohort study of incident SGLT\u20102i users was then conducted to describe patient characteristics and the strategy for treating diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of SGLT\u20102i use gradually reached 0.1% in the third quarter of 2021 and increased more significantly to 0.2% thereafter. SGLT\u20102i became the second most prescribed glucose\u2010lowering drug class after metformin at the end of 2021 (0.1%). Among the cohort of 125\u2009387 SGLT\u20102i new users (mean age 65.0\u2009years; 60.1% of men), 87.6% presented a diabetic comorbidity. The patient profile changed over the study period with an increasing proportion of patients with cardiovascular (28.7% in 2020 vs. 40.2% in 2021) or renal (7.7% in 2020 vs. 11.8% in 2021) comorbidities at initiation. The main combinations used at SGLT\u20102i initiation were metformin (12.5%) and metformin plus dipeptidyl peptidase\u20104 inhibitors (8.1%). One\u2010year probability of SGLT\u20102i persistence was estimated to be 55%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The expansion of indications for SGLT\u20102i and the broadening of the target population make it essential to assess the reasons for discontinuation and review their safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15472","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T05:14:12Z","timestamp":1706591652000},"page":"1678-1686","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Use of sodium\u2010glucose cotransporter\u20102 inhibitors in France: Analysis of French nationwide health insurance database"],"prefix":"10.1111","volume":"26","author":[{"given":"Sibylle","family":"de Germay","sequence":"first","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219 Team AHeaD  Bordeaux France"},{"name":"Department of Medical Pharmacology CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Pambrun","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219 Team AHeaD  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219 Team AHeaD  Bordeaux France"},{"name":"Department of Medical Pharmacology CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Grenet","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacotoxicology Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219 Team AHeaD  Bordeaux France"},{"name":"Department of Medical Pharmacology CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-4073","authenticated-orcid":false,"given":"Jean\u2010Luc","family":"Faillie","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology and Toxicology CHU Montpellier; Univ Montpellier, IDESP INSERM  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221174"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14408"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01320-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022768"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13877"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14947"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30369-7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1432"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30384-5"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03539-8"},{"key":"e_1_2_10_18_1","volume-title":"Historique des avis HAS \u2010 dapagliflozine Forxiga\u00ae","author":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"e_1_2_10_19_1","volume-title":"Historique des avis HAS \u2010 empagliflozine Jardiance\u00ae","author":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"e_1_2_10_20_1","unstructured":"Masson E.Prise de position de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD)\u2009: \u00e9valuation du rapport b\u00e9n\u00e9fices\u2010risques des inhibiteurs de SGLT2. EM\u2010Consulte.https:\/\/www.em-consulte.com\/article\/1285340\/prise-de-position-de-la-societe-francophone-du-dia."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.01.009"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_10_26_1","unstructured":"Estimation de la population au 1erjanvier 2023 | Insee.https:\/\/www.insee.fr\/fr\/statistiques\/1893198."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01140-1"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.01.009"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12187"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.03.002"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098099"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00785-1"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001238"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01110-w"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:51:27Z","timestamp":1761886287000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/dom.15472"],"URL":"https:\/\/doi.org\/10.1111\/dom.15472","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15472\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15472\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15472\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15472\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15472\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15472\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"2023-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}